Glibenclamide is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.
Sulphonylureas like glibenclamide have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
0.2 - 0.6 mg per kg of body weight
From 0.1 To 0.3 mg per kg of body weight 2 time(s) per day every day
To avoid exceeding sodium benzoate acceptable daily dose, glibenclamide daily dose should not exceed 1 mL/kg/day. As a consequence, glibenclamide 0.6 mg/mL should not be used for posology higher than 0.6 mg/kg/day.
To limit exposure to sodium benzoate and with respect to the mode of delivery (1 mL and 5 mL oral syringes), it is not recommended to use the glibenclamide 0.6 mg/mL strength for posologies higher than the ones described below:
| Body weight (kg) | Maximum recommended posology (expressed as mg/kg/day) where the glibenclamide 0.6 mg/mL strength can be used |
|---|---|
| Up to 10 | 0.6 |
| 11 | 0.5 |
| 12 | 0.5 |
| 13 | 0.4 |
| 14 | 0.4 |
| 15 | 0.4 |
| 16 | 0.3 |
| 17 | 0.3 |
| 18 | 0.3 |
| 19 | 0.3 |
| 20 | 0.3 |
In any other cases, glibenclamide 6 mg/mL should be preferred.
Glibenclamide therapy should be initiated at 0.2 mg/kg per day in two divided doses before feeding (including bottle feeding) and increased by 0.2 mg/kg/day until insulin independence is achieved
Since glibenclamide is administered with an oral syringe graduated in mL, the calculated daily dose should be expressed in mL by the physician explicitly stating the strength to be used.
The syringe will be chosen (1 mL or 5mL) based on the volume in mL to be administered for each dose, as prescribed by the physician. The 5 mL syringe has to be used for volumes greater than 1 mL.
The nearest volume to the calculated one should be used.
Patients should be closely monitored by their treating physician during the titration phase.
Start glibenclamide at a dose of 0.2 mg/kg/day, in two administration. Give basal and bolus insulin as usual on Day 1. On Day 2, if administered sub-cutaneously, basal insulin can be removed. If on insulin pump, reduce basal rate of insulin pump by 50% and reduce further in accordance with capillary blood-glucose measurements. Throughout the transfer period, administer bolus insulin or insulin pump boluses with meals as required to maintain reasonable glycemic control. From Day 2 until the end of the titration phase, if capillary blood glucose is ≥7 mmol/L, increase glibenclamide by 0.2 mg/kg/day . If capillary blood glucose is <7 mmol/L, do not increase glibenclamide and reduce pre-meal insulin boluses by 50%.
Pre-breakfast glucose may be very slow to fall. Pre-lunch or pre-evening meal glucose values fall more rapidly and are generally a better marker of response to glibenclamide.
Repeat the same protocol every day until insulin independence is achieved. As soon as insulin is discontinued, the dose of glibenclamide is adjusted according to capillary blood glucose.
For patients still under insulin at day 6, maintain the dose of glibenclamide for at least 4 weeks. This may be done as an outpatient.
Patients can be discharged when no longer requiring insulin treatment, when stable on a combination of glibenclamide and insulin or when stable on insulin alone.
Glibenclamide should be introduced at a dose of 0.2 mg/kg/day in two administration and dose should be progressively increased each week by 0.2 mg/kg/day.
As the dose is increased, it is usually possible to reduce and then stop the insulin dose.
From week 2 onward, if capillary blood glucose is ≥7 mmol/L increase glibenclamide by 0.2 mg/kg/day and reduce insulin. If capillary blood glucose is <7 mmol/L reduce insulin.
If blood-glucose value increases after insulin reduction, then increase glibenclamide by 0.2 mg/kg/day. Insulin reduction should be done using the pre-meal glucose.
Repeat the same protocol every week until insulin independence is achieved. As soon as insulin is discontinued, the dose of glibenclamide is adjusted according to capillary blood glucose.
If at the end of a 5 to 6-week period, there is no evidence of a response with insulin doses similar to those at starting, administration of doses up to 2 mg/kg/day for a week may be tried. (In rare cases, it has taken 4 months to wean off insulin completely).
If there is a clear reduction in insulin requirement at this dose of 2 mg/kg/day (reduction in insulin to at least 60% of pre-glibenclamide dose), then it is worth continuing a higher dose of glibenclamide over a prolonged period of time in selected cases.
As shown in the literature and in the clinical studies performed with glibenclamide, the average daily dose is expected to be around 0.2 to 0.5 mg/kg/day in most of the patients suffering from neonatal diabetes. Higher doses have occasionally been observed and doses up to 2.8 mg/kg/day have been successfully given without adverse reactions, according to literature. In case of a partial response on lower doses, as shown by reduced insulin requirements, a further dose increase up to 2.8 mg/kg/day may be tried in selected cases. In some children glycemic control can be better achieved when glibenclamide is administered 3 times or 4 times daily.
If no improvement is seen (unchanged insulin dose, similar glycaemic control and no improvement in neurology), glibenclamide should be discontinued.
During titration period patients' capillary blood-glucose concentration should continue to be monitored four times a day and at bedtime, as insulin requirements may continue to fall, or glibenclamide may need to be titrated. Once steady state is reached, capillary blood glucose does no longer need to be daily monitored except in clinical situations at risk of metabolic unbalance (see below). In all cases, HbA1c must be monitored every three months.
Sometimes, blood-glucose concentration will fall even though the patient is on a fixed dose of glibenclamide. Therefore, to avoid hypoglycaemia, consideration should be given to reducing the dose of glibenclamide or stopping treatment.
Reduction of glibenclamide dose should be anticipated by the treating physician and certainly if the glucose values are going below 4 mmol/L (72 mg/dL).
It may be necessary to adjust the dosage of glibenclamide in patients suffering from intercurrent infections, trauma, shock or anaesthesia:
Patients occasionally may have very high glucose values, i.e. >20 mmol/L (>360 mg/dL). In some cases these high glucose values seem to settle with the normal dose of glibenclamide. However, close monitoring of blood-glucose is required in all cases (please also refer to recommendations given under the heading “dose omission” further below) and adequate measures to restore euglycemia (e.g. application of a third daily glibenclamide dose or insulin) must be taken.
Glibenclamide is not bioequivalent with (crushed) tablets containing the same amount of glibenclamide.
If a dose is forgotten, there is a risk of hyperglycaemia. Blood-glucose level must be checked immediately and glibenclamide taken as soon as possible. If the blood-glucose level exceeds 16.5 mmol/L, the presence of ketonuria or ketonaemia must also be checked. If ketone bodies are present, an insulin injection must be given rapidly to restore the metabolic situation. The attending specialist should then be contacted.